


Asenapine

Cat. No.:	HY-10121		
CAS No.:	65576-45-6		
Molecular Formula:	C ₁₇ H ₁₆ ClNO		
Molecular Weight:	285.77		
Target:	5-HT Receptor; Adrenergic Receptor; Dopamine Receptor; Histamine Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling; Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 200 mg/mL (699.86 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.4993 mL	17.4966 mL	34.9932 mL
		5 mM	0.6999 mL	3.4993 mL	6.9986 mL
10 mM		0.3499 mL	1.7497 mL	3.4993 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.75 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (8.75 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.75 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of serotonin receptors (pK _i : 8.4-10.5), adrenoceptors (pK _i : 8.9-9.5), dopamine receptors (pK _i : 8.9-9.4) and histamine receptors (pK _i : 8.2-9.0). Asenapine can be used in the research of schizophrenia and bipolar disorder ^{[1][2]} .			
IC₅₀ & Target	5-HT _{1A} Receptor 8.6 (pKi)	5-HT _{1B} Receptor 8.4 (pKi)	5-HT _{2A} Receptor 10.2 (pKi)	5-HT _{2B} Receptor 9.8 (pKi)
	5-HT _{2C} Receptor	5-HT ₅ Receptor	5-HT ₆ Receptor	5-HT ₇ Receptor

	10.5 (pKi)	8.8 (pKi)	9.6 (pKi)	9.9 (pKi)
	Alpha-2A adrenergic receptor 8.9 (pKi)	α 1-adrenergic receptor 8.9 (pKi)	Alpha-2B adrenergic receptor 9.5 (pKi)	Alpha-2C adrenergic receptor 8.9 (pKi)
	D ₁ Receptor 8.9 (pKi)	D ₂ Receptor 8.9 (pKi)	D ₃ Receptor 9.4 (pKi)	D ₄ Receptor 9.0 (pKi)
	H ₁ Receptor 9.0 (pKi)	H ₂ Receptor 8.2 (pKi)		

In Vivo

Asenapine (0.05-0.2 mg/kg; s.c.) induces a dose-dependent suppression of conditioned avoidance response (CAR) and does not induce catalepsy^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Wistar rats (200-250 g) ^[2]
Dosage:	0.05 mg/kg, 0.1 mg/kg, 0.2 mg/kg
Administration:	Subcutaneous injection
Result:	Produced suppression of CAR in a dose-dependent manner.

CUSTOMER VALIDATION

- Int J Biol Macromol. 2023 Jul 4;125703.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. M Shahid, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73.

[2]. Olivia Frånberg, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl). 2008 Feb;196(3):417-29.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA